Clinical trial
An Open-label Study of UX003 rhGUS Enzyme Replacement Therapy in MPS 7 Patients Less Than 5 Years Old
NCT02418455 is registered in ClinicalTrials.gov with Ultragenyx Pharmaceutical Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Study of UX003 rhGUS Enzyme Replacement Therapy in MPS 7 Patients Less Than 5 Years Old
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 21, 2015
- Completion date
- March 26, 2019
- Enrollment
- 8 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
mps vii, mucopolysaccharidosis, mucopolysaccharidosis vii, sly syndrome